The phase 3 MRC COIN trial showed no statistically significant benefit from adding the EGFR-target cetuximab to oxaliplatin-based chemotherapy in first-line treatment of advanced colorectal cancer. This study exploits additional information on HER2-HER3 dimerization to achieve patient stratification and reveal previously hidden subgroups of patients who had differing disease progression and treatment response. Methods: HER2-HER3 dimerization was quantified by "FLIM Histology" in primary tumor samples from 550 COIN trial patients receiving oxaliplatin and fluoropyrimidine chemotherapy +/-cetuximab. Bayesian latent class analysis (LCA) and covariate reduction was performed to analyze the effects of HER2-HER3 dimer, RAS mutation and cetuximab on progression-free survival (PFS) and overall survival (OS). All statistical tests were twosided. Results: LCA on a cohort of 398 patients revealed two patient subclasses with differing prognoses (median OS: 1624 days [95%CI=1466-1816] vs 461 [95%CI=431-504]): Class 1 (15.6%) showed a benefit from cetuximab in OS (HR=0.43 [95%CI=0.25-0.76];
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The selection of patients who are likely to benefit from treatment with an EGFR inhibitor with first line chemotherapy for metastatic colorectal cancer (mCRC) remains controversial. Two major trials have compared the addition of cetuximab or bevacizumab for patients with KRAS wildtype colorectal cancer [1] [2] [3] . FIRE-3 showed a statistically significant survival benefit from cetuximab, in contrary to the US-based CALGB 0405 study, leading to intense debate [4] . Results show markedly improved overall survival (OS) compared to older trials, partially driven by the selection of the better prognosis KRAS wildtype population. The presence of any extended RAS mutation [5] was demonstrated to exclude patients from benefit of panitumumab in the PRIME trial; this is now enshrined in license [6] .
Other molecular factors also influence responsiveness to the addition of an EGFR inhibitor: the presence of a BRAF mutation and low expression of key EGFR ligands, epiregulin (EREG) or amphiregulin (AREG), both predict a lack of benefit [7, 8] . The primary tumor's site of origin is also important. Tumors arising from the right, midgut derived, colon, falling in the arterial supply of the superior mesenteric artery, are more frequently methylated (with resulting low expression of EGFR ligands) [9] [10] [11] , more often have mismatch repair deficiency, and carry a RAF mutation [12] [13] [14] . Left-sided cancers more often exhibit those features of responsiveness to EGFR treatment, namely high ligand expression and RAS and RAF wildtype. Initial reports also indicated that PIK3CA mutations may be associated with diminished responsiveness but these conclusions were from small studies (2-11 patients with PIK3CA mutations) [15, 16] . Larger studies did not show a statistically significant difference [17, 18] , with the exception of one study showing that PIK3CA exon 20 mutation confers a poorer outcome [19] . Despite all this, reliable methods for the identification of patients who may benefit from EGFR antibody therapy remain elusive.
In this paper we describe a novel approach to this problem. It is known that HER (ErbB) mediated signaling is initiated following dimerization between the same (homodimerization) or different HER family members (EGFR, ErbB/HER1-4) [20] . Dimers containing HER3, especially the HER2-HER3 heterodimer, have been shown to provide the most potent proliferative signal to cancer cells [21] . Recently, we showed in preclinical experiments the HER2-HER3 can be modulated upon cetuximab treatment of colorectal cancer cells [22] . The same heterodimer has been demonstrated using archived primary breast cancer samples and contains statistically significant prognostic information which is independent of that of HER2 receptor expression status [23] . It is usually difficult to determine whether the receptors are forming dimers but the technique of Förster Resonance Energy Transfer (FRET) reports on the immediate proximity, only achieved during dimerization. The combination of FRET with time-domain Fluorescence Lifetime Imaging Microscopy (FLIM) allows the minute fluorescence signals to be detected [24] . Hence FRET-FLIM represents the most exquisitely sensitive method for determining what proportion of a receptor is dimerized.
Here we report the use of "FLIM Histology", a technique using FRET-FLIM as a measure of the proportion of receptors in the HER2-HER3 dimer state, a concentration independent parameter, based on a well-established gold standard technique to probe endogenous protein-protein interactions in cells [23, [25] [26] [27] [28] [29] [30] . In 550 patients from the MRC COIN trial [31] , combining the use of HER dimer measurement and recently reported Bayesian statistical methods [32] [33] [34] , we aimed to identify subclasses of patients with different prognostic outcomes.
MATERIALS AND METHODS

Patients and Treatment
In the MRC COIN trial (ISRCTN79877428) [31] patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease (RECIST v1.0), and were fit for first line combination chemotherapy, were randomized in a 1:1:1 ratio to receive the control arm of continuous oxaliplatin-based chemotherapy (A), or continuous chemotherapy plus cetuximab (B), or intermittent chemotherapy (C). This study was restricted to arms A and B. Two chemotherapy regimens, XELOX or OxMdG (oxaliplatin with modified deGramont, a FOLFOX variant), were used.
Objectives and Outcome Measures
The primary objective of the COIN A vs B comparison was to determine whether the addition of cetuximab to continuous chemotherapy resulted in improved outcome in patients with KRAS wildtype (WT) tumors. Overall Survival (OS) was calculated as time from randomization to death from any cause. Survivors were censored at the last known alive date. Progression Free Survival (PFS) was calculated as the interval from randomization to first evidence of progression or death from any cause. Survivors without progression were censored at the last known alive date.
Patient Samples and Imaging
This study was approved by the Trial Steering Committee and FRET-FLIM was limited to those patients who had given written informed consent for 'other bowel cancer research', in whom sufficient residual pathological specimen was available.
Patient tissue micro-arrays (TMAs) were retrieved from the Wales Cancer Bank and processed at King's College London. Two consecutive slices of all TMAs underwent antigen retrieval in a Ventana BenchMark system and were stained with anti-HER3-IgG-Alexa546 ('donor' or 'D' slice) and in addition with anti-HER2-IgG-Cy5 ('donor with acceptor' or 'DA' slice) and mounted as described previously [26] .
TMA slices were imaged on an "open" automated FLIM microscope [35] . FLIM analysis was performed with the TRI2 software (v2.7.8.9, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford) [36] [37] [38] . Autofluorescence effects were minimized with a lifetime filtering algorithm [39] . The FRET efficiency for each tissue region was calculated according to FRET efficiency = 1-(DA/D), where D and DA are the average lifetime of Alexa546 in the matching D and DA images respectively. FRET efficiency (denoted: "FRET"), and FRET efficiency multiplied by HER3 fluorescence intensity, representing the amount of dimerized HER3, ("FRET x HER3") were calculated as continuous variables (Supplementary Figure 1) .
The use of formol saline fixation, as opposed to neutral buffered formalin, resulted in excessive amounts of contaminating autofluorescence. These samples (292 patients) were excluded.
TMAs from the 398-patient training set and the 152-patient validation set were received and processed independently in two batches. All analysis of the training set was performed before the validation TMAs were received, and was therefore performed completely blind and without knowledge of the validation set.
Statistical Analysis
Bayesian latent class analysis (LCA) was performed using the model described by
Rowley et al. [32] (ALPACA v0.2.15), which seeks to detect and map association and base hazard rate heterogeneity. This results in objective cohort stratification, driven strictly by observed and statistically significant regularities in the data. Specification of the number of latent classes and the complexities of class-dependent base hazard rates, is based on Bayesian model selection. Patients were retrospectively assigned to latent groups according to maximum a posteriori class membership probability.
Covariate reduction and the generation of predictive signatures was performed by
Bayesian multivariate survival analysis with repeated cross-validation and backwards elimination with the aim of reducing overfitting [33] .
Kaplan-Meier plots and log-rank statistics were produced using the R 'survival' package (v2.42-3, R v3.5.1). When p<0.05 the result was considered statistically significant and all tests were two-sided.
RESULTS
Tissues from two cohorts of 398 and 152 patients (the 'FRET' training and validation cohorts respectively) were analyzed for HER2-HER3 dimerization. All patients also formed a 'full' cohort of 1,630 patients. Figure 1 summarizes the patient selection for imaging and analysis and Table 1 contains the cohort patient characteristics. A continuous distribution of FRET efficiency with a mean value of 1.6%, (lower quartile 0.18%, upper quartile 2.7%) was recorded. Figure 2 shows typical images and FRET efficiency maps.
LCA was performed on the FRET training cohort for both outcomes using, a minimal, 4 covariates: FRET; FRET x HER3 (since HER protein concentration information is independent of dimer [40] ); Treatment Arm (to give the algorithm the ability to detect groups with different responses); and RAS mutation status (because of its known association with cetuximab treatment).
We report evidence of two novel latent classes in the 398-patient training set, with both PFS and OS analysis. The hazard ratios (HR) assigned to each covariate for each class is shown in Figure 3A Figure 3E -F shows Kaplan-Meier curves split by class and FRET demonstrating the benefit of cetuximab to those with a high FRET score. FRET x HER3 did not have a statistically significant HR. Table 2 shows the characteristics of the patient classes and gives an indication of which parameters may be useful in a prospective patient classifier (p<0.05): FRET ( Supplementary Figure 2) , liver-only metastases, PIK3CA mutation status, RECIST sum of longest diameter, neutrophil count, white blood cell count, pain at baseline, haemoglobin and alkaline phosphatase.
Additional LCA was performed without the FRET parameters and determined that there was insufficient evidence for distinct latent groups. The HER2-HER3 FRET efficiency data therefore conveys significant additional information.
As validation of this class structure we sought further evidence in the full COIN cohort (1,630 patients, including FRET cohorts) for whom clinical and genomic data was available.
To maximize the utility of any findings for patient stratification we performed analysis with all available baseline covariates (115 covariates including missingness indicators, expanded categorical data and TRT, see Supplementary Methods). These were subject to Bayesian covariate reduction against OS and we identified a signature that combined 10 covariates (WHO performance status, previous adjuvant chemotherapy status, RECIST sum of longest diameter, number of metastatic sites, EREG, RAS status (KRAS or NRAS), BRAF status, neutrophil count, alkaline phosphatase and pain). (N=1187/1630) shows a statistically significant negative response (HR=1.34 [95%CI=1.10-1.71], p=0.005). This is reflected in the Kaplan-Meier curve split by class and TRT ( Figure   4B ). PFS-based LCA did not reveal interesting classes.
To investigate the overlap in membership of individual patients between the classes of the two LCA analyses from the FRET cohort and the full cohort, the class membership table for the 398 FRET cohort patients is presented in Figure 4C . A permutations test (100,000 random permutations of 398 patients into classes in these proportions) indicated a probability of <1/100,000 for obtaining this overlap in membership by chance. LCA was also performed on the non-overlapping set of 1,232 patients (1,630 minus 398) and a similar three groups were found (See Supplementary Figure 3 ).
In the FRET cohort there was a statistically significant association of PIK3CA mutation with better OS (median 875 vs 504 days, logrank p=0.03, Supplementary Figure 4 ), which agrees with the observation of a higher proportion of PIK3CA mutant in the responding Class 1. This association was not detectable in the full cohort. A breakdown into exon 9 or exon 20 PIK3CA mutation groups did not reveal any statistically significant differences in PFS or OS, in either cohort (FRET cohort: exon 9, N=37/398, exon 20, N=12/398; full cohort exon 9, N=106/1630, exon 20, N=50/1630).
To form a covariate signature that may predict class membership we performed Bayesian covariate reduction on the union of the nine covariates identified in Table 2 and the 10 prognostic baseline covariates: total 15. The resulting signature contained seven statistically significant covariates (RECIST sum of longest diameter, neutrophil count, white blood cell count, haemoglobin, PIK3CA mutation status, liver-only metastases and FRET) with associated weights (Figure 5A) .
The performance against the LCA class assignment of the 398 is shown in Figure 5B (AUC: 0.753). The signature was used as a classifier, by selecting an optimal point on the ROC curve (according to Youden's index) with specificity of 0.677 and sensitivity of 0.708.
The results on the 398 training set and the independent validation set of 152 are shown in Another signature was produced without FRET (from 14 parameters, Figure 5E) and 
DISCUSSION
The selection of patients for EGFR-inhibitor treatment for mCRC remains difficult. With KRAS WT patients, the addition of EGFR-targeted treatment (cetuximab/panitumumab) to irinotecan or oxaliplatin chemotherapy [1, 6, 41, 42] , is associated with a statistically significant survival benefit in three of four phase 2/3 trials [1, 6, 42] . However, the improvement of median PFS was only around 1-2 months. In the phase 2 OPUS trial, addition of cetuximab to FOLFOX4 resulted in a statistically significant improvement in PFS (8.3 months vs 7.2 months, p=0.006) [42] . In contrast, the NORDIC VII trial reported no benefits from adding cetuximab to oxaliplatin-based regimen (with bolus 5-FU) [41] . EGFR immunohistochemistry is not a sufficient predictive factor for clinical benefit for cetuximab in the KRAS WT population [43, 44] .
Further molecular stratification by identifying novel subgroups will make a meaningful contribution towards assessing the efficacy of EGFR targeting in future clinical trials. Here we present the application of our recently improved and validated [23] FLIM Histology analysis method for quantification of HER2-HER3 dimer in FFPE samples from the randomized phase 3 MRC COIN trial. Using FLIM-based molecular imaging parameters and a recently published Bayesian statistical method [32] we have shown that there are two classes of patients with mCRCTable 2, Figure 3 . Class 1 (10-15% of patients) had a better prognosis and also benefited from addition of cetuximab to the standard chemotherapy.
Within Class 2 (85-90% of patients), patients have less favorable survival (median PFS circa 7.5 months) and no benefit from cetuximab.
To validate these results we formed a biomarker that predicts class membership by creating a novel signature of seven parameters that were pre-determined by the two Bayesian latent class analyses. This was applied to the training set of 398 and we retained the predictive and prognostic elements of, the smaller, Class 1. Notably, the prognostic effect on survival (195 days, comparing chemotherapy only patients between Classes 1 and 2) was larger than the predictive effect (136 days, comparing Class 1 patients with/without cetuximab). Application of the signature to the completely independent validation set of 152 patients was sufficient to validate the prognostic (but not the predictive) utility. In addition, we found that patients exhibiting a high FRET value are more likely to be in the worst prognostic outcome subclass i.e. Class 2 ( Table 2) as reflected in the class prediction signature ( Figure   5A ). However, within Class 2 a high FRET value can be indicative of better outcome within that class dependent on the other signature covariates. Importantly, the class prediction (seven-parameter) signature is entirely dependent on the inclusion of the HER2-HER3 dimer quantity.
We chose HER2-HER3 because it has been shown to be the most tumor promoting dimer among EGFR family members, due to its downstream activation of PI3-kinase (PI3K)/AKT and MAPK pathways [45] [46] [47] . Secondly, the mRNA expression of alternative ligands such as EREG, which has been shown to modulate the efficacy of EGFR-targeted agents in KRAS WT mCRCs [7] , is the broadest specificity EGF-like ligand that induces the widespread phosphorylation of HER1-4 [48] . Although the mechanism of this modulation is not precisely known, EREG, as opposed to EGF, can recruit HER3 into heterodimers, as reflected by its enhancement on the proliferative activity on cells co-expressing a combination of HER3 with either HER2 or HER4 [49] . Thirdly, we showed by FRET-FLIM imaging, an induction of HER2-HER3 dimers after cetuximab treatment in KRAS and BRAF WT colon cancer cells [22] .
The additional HER2-HER3 dimer parameter as measured by FLIM may be important for the future stratification of anti-HER2 treatment combination using pertuzumab plus trastuzumab [50] . Notably, HER2 activity (of prognostic signature) has been shown previously to be measurable by FLIM independently of HER2 concentration [23] .
This new retrospective analysis suggests that the proportion of patients gaining benefit from cetuximab may be as small as 10% and concurs with clinical data that these patients are amongst those with the best baseline prognosis. HER2-HER3 FRET-FLIM provided new information enabling the statistical method to identify this latent class. This hypothesis generating data shows the potential of measurement of dimers and demonstrates the utility of FRET-FLIM to assess dimerization in FFPE tissue.
Further preclinical experiments, using patient derived organoids for example, are needed to understand the statistically significantly increased prevalence of PIK3CA mutations in the discovered Class 1. Previously anti-EGFR response was shown to be higher for RAS WT patients who expressed pEGFR and pAkt [51] . pAkt may in turn be linked to EGFR trafficking and degradation, and therefore treatment response, warranting further study [52] . Furthermore, the predictive utility of this assay may be further enhanced by the inclusion of pre-and post-treatment dimer measurements as we have recently demonstrated in a Phase 2 head and neck study using an exosomal HER dimer assay [53] .
In conclusion, this study demonstrates how a novel Bayesian LCA, signature generation and covariate reduction can be used as objective approaches to generate hypotheses for treatment. Given that the identification of prognostic and predictive biomarkers and clinical characteristics in colorectal cancers is an active area of research, this study shows how the development and application of statistical methods contributes to the retrospective analysis of trials. The ability to model and quantify the evidence for putative patient stratifications is therefore a crucial initial step towards identifying and validating strategies for targeting therapies. 
